Ranexa's new script

While CV Therapeutics Inc. got everything it asked FDA for in its expanded label for Ranexa ranolazine, cardiologists predict doctors will need to see the drug's newly approved benefits for themselves before they begin to prescribe the late sodium current blocker over standard beta blockers as the first-line treatment of choice for patients with chronic angina.

The changes FDA approved in November include an sNDA to add first-line treatment of chronic angina and to reduce cautionary language about QTc prolongation...